Isatuximab SAR650984 for Multiple Myeloma

"At this time, no more candidates are being accepted for this trial. It was initially posted on January 25th 2018 and the data was last updated October 12th 2022. If you're in search of other medical studies, 818 trials related to neoplasms or plasma cells are presently recruiting patients as well as 100 trials specifically dedicated to Isatuximab SAR650984."

"alK gene mutation can be managed with Isatuximab SAR650984, which has also been found to treat conditions such as pre-existing medical directives and malignant neoplasms. It is especially beneficial for patients who have attempted other treatments like lenalidomide or proteasome inhibitor therapies before."

"Isatuximab SAR650984 was initially studied in City of Hope during the year 2010. 11 clinical trials have been completed and there are 100 active studies, many of which take place in Montreal and Pennsylvania."

"Information available on clinicaltrials.gov states that this medical trial is not taking applications at the current time, even though it was initially posted in January 2018 and last updated October 12th 2022. Nevertheless, there are over 900 other studies looking for participants right now."

"The primary purpose of this trial, assessed over a period spanning up to 4 weeks, is to analyse Adverse Events (AEs) and changes in laboratory tests and vital signs. Secondary goals include measuring Antibodies to cemiplimab levels in the blood serum samples; calculating Duration of Response (DOR); as well as determining amount of anti-isatuximab antibodies present in plasma specimens."

"Currently, this medical trial is available at 7 different sites, located in Montreal, Sherbrooke and Philadelphia as well as other locations. To reduce any travel needs associated with participation, it would be beneficial to select the closest clinic."